StockData
Pure Bioscience, Inc. logo

Pure Bioscience, Inc. (PURE) stock

PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 29, 2026Score 1/30
$0.07−0.01 (-12.10%)

Close on Oct 19, 2026Market cap $8.67MP/E –Yield –

Pure Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pure Bioscience's operating income for the twelve months ending Jul 31, 2026 was -$2.08M. For fiscal 2026 it was -$2.08M. The highest annual figure on record is $4.00K in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2026Jul 31, 2026-$2.08M–
FY2025Jul 31, 2025-$2.27M–
FY2024Jul 31, 2024-$3.19M–
FY2023Jul 31, 2023-$3.94M–
FY2022Jul 31, 2022-$3.72M–
FY2021Jul 31, 2021-$2.31M-57875.0%
FY2020Jul 31, 2020$4.00K–
FY2019Jul 31, 2019-$5.59M–
FY2018Jul 31, 2018-$7.04M–
FY2017Jul 31, 2017-$6.01M–
FY2016Jul 31, 2016-$7.06M–
FY2015Jul 31, 2015-$7.64M–
FY2014Jul 31, 2014-$11.90M–
FY2013Jul 31, 2013-$7.34M–
FY2012Jul 31, 2012-$8.75M–
FY2011Jul 31, 2011-$8.37M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jul 31, 2026-$503.00K–
Q3 FY2026CQ1 2026Apr 30, 2026-$518.00K–
Q2 FY2026CQ4 2025Jan 31, 2026-$683.00K–
Q1 FY2026CQ3 2025Oct 31, 2025-$379.00K–
Q4 FY2025CQ2 2025Jul 31, 2025-$336.00K–
Q3 FY2025CQ1 2025Apr 30, 2025-$584.00K–
Q2 FY2025CQ4 2024Jan 31, 2025-$725.00K–
Q1 FY2025CQ3 2024Oct 31, 2024-$627.00K–
Q4 FY2024CQ2 2024Jul 31, 2024-$699.00K–
Q3 FY2024CQ1 2024Apr 30, 2024-$817.00K–
Q2 FY2024CQ4 2023Jan 31, 2024-$964.00K–
Q1 FY2024CQ3 2023Oct 31, 2023-$711.00K–
Q4 FY2023CQ2 2023Jul 31, 2023-$1.02M–
Q3 FY2023CQ1 2023Apr 30, 2023-$875.00K–
Q2 FY2023CQ4 2022Jan 31, 2023-$1.06M–
Q1 FY2023CQ3 2022Oct 31, 2022-$986.00K–
Q4 FY2022CQ2 2022Jul 31, 2022-$1.23M–
Q3 FY2022CQ1 2022Apr 30, 2022-$759.00K–
Q2 FY2022CQ4 2021Jan 31, 2022-$940.00K–
Q1 FY2022CQ3 2021Oct 31, 2021-$795.00K–
Q4 FY2021CQ2 2021Jul 31, 2021-$728.00K-155.0%
Q3 FY2021CQ1 2021Apr 30, 2021-$810.00K-270.9%
Q2 FY2021CQ4 2020Jan 31, 2021-$594.00K–
Q1 FY2021CQ3 2020Oct 31, 2020-$179.00K–
Q4 FY2020CQ2 2020Jul 31, 2020$1.32M–
Q3 FY2020CQ1 2020Apr 30, 2020$474.00K–
Q2 FY2020CQ4 2019Jan 31, 2020-$663.00K–
Q1 FY2020CQ3 2019Oct 31, 2019-$1.13M–
Q4 FY2019CQ2 2019Jul 31, 2019-$822.00K–
Q3 FY2019CQ1 2019Apr 30, 2019-$912.00K–
Q2 FY2019CQ4 2018Jan 31, 2019-$1.29M–
Q1 FY2019CQ3 2018Oct 31, 2018-$2.56M–
Q4 FY2018CQ2 2018Jul 31, 2018-$1.38M–
Q3 FY2018CQ1 2018Apr 30, 2018-$1.71M–
Q2 FY2018CQ4 2017Jan 31, 2018-$2.03M–
Q1 FY2018CQ3 2017Oct 31, 2017-$1.93M–
Q4 FY2017CQ2 2017Jul 31, 2017-$1.41M–
Q3 FY2017CQ1 2017Apr 30, 2017-$1.59M–
Q2 FY2017CQ4 2016Jan 31, 2017-$1.40M–
Q1 FY2017CQ3 2016Oct 31, 2016-$1.60M–

More Pure Bioscience figures

See a number that looks wrong?